Target Name: KLK1
NCBI ID: G3816
Other Name(s): KLK1_HUMAN | Klk6 | Kallikrein-1 | KLKR | kallikrein serine protease 1 | glandular kallikrein 1 | kallikrein 1 | hK1 | Kidney/pancreas/salivary gland kallikrein | tissue kallikrein | Tissue kallikrein | kallikrein 1, renal/pancreas/salivary | Glandular kallikrein 1 | Kallikrein serine protease 1 | kidney/pancreas/salivary gland kallikrein | Kallikrein 1 | HK

KLK1: A Potential Drug Target for Various Diseases

KLK1 (KLK1-HUMAN) is a gene that encodes a protein known as KLK1. KLK1 is a member of the K-type ATP-binding proteins (K-ATPases) family, which are a group of transmembrane proteins that play an important role in various cellular processes. KLK1 is expressed in many different tissues and cells throughout the body, including muscle, heart, brain, and organs.

One of the unique features of KLK1 is its ability to act as an ATPase, which means it can catalyze the hydrolysis of ATP to release energy. This process is critical for many cellular functions, including muscle contractions, nerve impulse transmission, and brain function . In addition, KLK1 can also act as a negative regulator of the RAS/MAPK signaling pathway, which is involved in many cellular processes, including cell growth, differentiation, and survival.

KLK1 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in cancer progression. For example, studies have shown that KLK1 can inhibit the activation of the ERK1/2 signaling pathway, which is associated with the growth and survival of many cancer cells. Additionally, KLK1 has also been shown to play a role in the regulation of the PI3K/AKT signaling pathway, which is involved in the regulation of many cellular processes, including cell survival and metabolism.

KLK1 is also a potential drug target in the treatment of various diseases. For example, KLK1 has been shown to be involved in the development and progression of cardiovascular disease, which is a leading cause of death in many countries. Studies have shown that KLK1 can be expressed in the hearts of mice and that its expression is associated with the development ofcardiovascular disease. In addition, KLK1 has also been shown to be involved in the regulation of muscle contractions, which is critical for normal muscle function. Therefore, KLK1 may be a useful target for the development of new treatments for cardiovascular and muscle-related diseases.

In conclusion, KLK1 is a gene that encodes a protein that plays a critical role in various cellular processes throughout the body. Its unique ability to act as an ATPase and its role in the regulation of multiple signaling pathways make it a potential drug target for the treatment of various diseases. Further research is needed to fully understand the role of KLK1 in cellular processes and its potential as a drug target.

Protein Name: Kallikrein 1

Functions: Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin

More Common Targets

KLK10 | KLK11 | KLK12 | KLK13 | KLK14 | KLK15 | KLK2 | KLK3 | KLK4 | KLK5 | KLK6 | KLK7 | KLK8 | KLK9 | KLKB1 | KLKP1 | KLLN | KLRA1P | KLRB1 | KLRC1 | KLRC2 | KLRC3 | KLRC4 | KLRC4-KLRK1 | KLRD1 | KLRF1 | KLRF2 | KLRG1 | KLRG2 | KLRK1 | KLRK1-AS1 | KMO | KMT2A | KMT2B | KMT2C | KMT2CP4 | KMT2D | KMT2E | KMT2E-AS1 | KMT5A | KMT5B | KMT5C | KNCN | KNDC1 | KNG1 | KNL1 | KNOP1 | KNOP1P5 | KNSTRN | KNTC1 | KPNA1 | KPNA2 | KPNA3 | KPNA4 | KPNA5 | KPNA6 | KPNA7 | KPNB1 | KPNB1-DT | KPRP | KPTN | KRAS | KRASP1 | KRBA1 | KRBA2 | KRBOX1 | KRBOX1-AS1 | KRBOX4 | KRBOX5 | KRCC1 | KREMEN1 | KREMEN2 | KRI1 | KRIT1 | KRR1 | KRT1 | KRT10 | KRT10-AS1 | KRT12 | KRT126P | KRT13 | KRT14 | KRT15 | KRT16 | KRT16P1 | KRT16P2 | KRT16P3 | KRT16P6 | KRT17 | KRT17P1 | KRT17P2 | KRT17P3 | KRT17P5 | KRT17P7 | KRT18 | KRT18P1 | KRT18P12 | KRT18P13 | KRT18P16 | KRT18P17